Roch Ogier

Roch Ogier has a diverse work experience spanning various roles in the pharmaceutical and healthcare industry. Starting in 2000, they worked as an MD-PhD fellow at the University of Geneva before joining the Hôpitaux Universitaires de Genève as a resident doctor. In 2007, they became the Medical Manager and later the Medical Director ad int. at Sanofi-Aventis Switzerland. Roch then worked as the Medical Director Switzerland at Vifor Pharma from 2009 to 2013. From 2013 to 2017, they served as the Chief Scientific Officer Switzerland at Novartis. Roch then transitioned to the University of Zurich as the Head of the Therapy Development Accelerator from 2017 to 2021. Roch Ogier was also a Board Secretary at UZH Life Sciences Fund from 2019 to 2021. Roch held the position of Venture Partner at Ataraxia Partners from 2020 to 2022. Currently, they are at OM Pharma, where they initially served as the Chief BD & Innovation Officer from 2021 to 2023 and is presently the Chief Operating Officer. Additionally, they founded and owns Firstmed SA since 2002.

Roch Ogier has an extensive education history. In 1994-2000, they attended the University of Geneva and obtained a Medical degree from the Faculté de Médecine. Roch then pursued further studies at the same university and earned a Master's Degree in Medical Biology from the Faculté des Sciences in 2000-2001. Roch continued their academic journey at the University of Geneva and completed a Doctor of Medicine (M.D.) degree in 2000-2006. During the same period, they also achieved a Doctor of Philosophy (Ph.D.) degree. In 2009-2011, Roch attended the University of Basel and obtained an Advanced Studies in Pharmaceutical Medicine degree. Subsequently, in 2015, they pursued Advanced Studies in eHealth at the IKF Institut für Kommunikation und Führung. Roch's education also includes an HEC - Advanced Studies in Healthcare Management degree from the University of Geneva in 2004-2005. Most recently, they attended the Swiss Board School and completed the Executive Program for Board Members in 2017-2018.